UPDATE -- Tonix Pharmaceuticals to Present at Dawson James Securities 2016 Small Cap Growth Stock Conference
October 18 2016 - 4:48PM
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is
developing a next-generation treatment for posttraumatic stress
disorder (PTSD), announced today that it will present at the Second
Annual Dawson James Securities Small Cap Growth Stock Conference
being held October 20, 2016 in Jupiter, Florida.
Seth Lederman, M.D., president and chief executive officer of
Tonix, will provide a corporate update and an overview of Tonix’s
PTSD clinical program. Tonix recently announced a successful
end-of-phase 2 meeting with the U.S. Food and Drug Administration
(FDA), as well as positive data from its randomized, double-blind,
placebo-controlled Phase 2 AtEase clinical trial evaluating TNX-102
SL in military-related PTSD. Dr. Lederman’s presentation will
include planned next steps for this program.
Event: |
|
|
Dawson James Securities 2016 Small Cap Growth
Stock Conference |
Date: |
|
|
Thursday, October 20, 2016 |
Time: |
|
|
4:30 PM (Eastern Time) |
Location: |
|
|
Wyndham Grand Jupiter at Harbourside Place,
Jupiter, Florida |
The presentation will be webcast live and remain
available for 90 days following the presentation. To access the
webcast, please visit the Events tab of the Investor Relations
section of Tonix’s website at www.tonixpharma.com.
TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an
Investigational New Drug and has not been approved for any
indication.
About Tonix Pharmaceuticals Holding Corp.
Tonix is developing next-generation medicines for common
disorders of the central nervous system, with its lead program
focusing on PTSD. This disorder is characterized by chronic
disability, inadequate treatment options, high utilization of
healthcare services, and significant economic burden. This press
release and further information about Tonix can be found at
www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Tonix's current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, substantial
competition; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties of government or
third party payor reimbursement; limited research and development
efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance
with FDA regulations. As with any pharmaceutical under development,
there are significant risks in the development, regulatory approval
and commercialization of new products. Tonix does not undertake an
obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in the Annual
Report on Form 10-K for the year ended December 31, 2015, as filed
with the Securities and Exchange Commission (the “SEC”) on March 3,
2016, and future periodic reports filed with the SEC on or after
the date hereof. All of Tonix's forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date hereof.
Contacts
Bradley J. Saenger, CPA
Chief Financial Officer
investor.relations@tonixpharma.com
(212) 980-9155 x107
Jessica Smiley
Investor Relations
investor.relations@tonixpharma.com
(212) 980-9155 x185
Edison Advisors (investors)
Tirth Patel
tpatel@edisongroup.com
(646) 653-7035
Dian Griesel Int’l (media)
Susan Forman / Laura Radocaj
sforman@dgicomm.com
lradocaj@dgicomm.com
(212) 825-3210
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2024 to May 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From May 2023 to May 2024